ClinConnect ClinConnect Logo
Search / Trial NCT06890962

Citicoline Dose on Energy Drink Efficacy

Launched by NATHANIEL JENKINS · Mar 20, 2025

Trial Information

Current as of April 30, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Fitness: Healthy, recreationally trained (\>2 d/wk physical activity)
  • BMI: (\<30kg/m2) or BF \<25% (M) and \<32% (F)
  • Exclusion Criteria:
  • \<1 hr/wk playing video games
  • \>=21 servings of \>=170.5 mL (or \>=6 fl oz) caffeine beverages per week \[(PMID: 33525438)\]
  • Injury or illness
  • Habitual nicotine or cannabis use
  • Use of prescription ADD/ADHD, anti-depressant, or other central acting medication, or previously diagnosed ADD/ADHD, clinical depression, or other mental health condition
  • Use of prescription, OTC, or dietary supplements to support sleep, or having been diagnosed with a clinical sleep condition
  • Current or prior chronic (\>6 mo) illicit drug or alcohol abuse
  • Clinically diagnosed with, or taking medication for a cardiometabolic disease or disorder (e.g., Pre-diabetes, Type II diabetes, high blood pressure, chronic kidney disease, cardiovascular disease, obesity, etc.)
  • Clinically diagnosed digestive disorder or sensitivity, or regular use of OTC or dietary supplements to support gastrointestinal pain or discomfort
  • Competitive athlete
  • Failure to comply with the controls and conditions of this study

About Nathaniel Jenkins

Nathaniel Jenkins is a dedicated clinical trial sponsor with a robust commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, Mr. Jenkins leads initiatives that prioritize safety, efficacy, and ethical standards in clinical trials. His expertise in trial design and regulatory compliance ensures that studies are conducted with the highest level of integrity and scientific rigor. Through collaboration with healthcare professionals and research institutions, Nathaniel Jenkins aims to facilitate the development of groundbreaking treatments that address unmet medical needs.

Locations

Iowa City, Iowa, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported